logo
logo

CollPlant and Stratasys Initiate Pre-clinical Study for Regenerative Commercial-Sized Breast Implants

Aug 19, 2024•11 months ago

Contract Type

partnership

RehovotBiotechnologyManufacturing

Description

CollPlant Biotechnologies and Stratasys Ltd. have announced the initiation of a pre-clinical study focused on the development of bioprinting solutions and testing the ability of the implants to promote the growth of natural breast tissue. The study aims to provide a revolutionary alternative for reconstructive and aesthetic procedures in the breast implant market.

Company Information

Company

CollPlant

Location

Rehovot, Center District, Israel

About

CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Related People